Capricor Therapeutics financials
$8.57−1.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $22.3M | $25.2M | $2.6M | $244.9K | $310.3K | $1.0M | $1.7M | $2.7M | $4.0M |
| Gross profit | $0.00 | $22.3M | $25.2M | $2.6M | $244.9K | $310.3K | $1.0M | $1.7M | $2.7M | $4.0M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$108.1M | -$42.6M | -$24.1M | -$29.7M | -$20.9M | -$13.7M | -$7.7M | -$15.3M | -$12.9M | -$18.5M |
| Net income | -$105.0M | -$40.5M | -$22.3M | -$29.0M | -$20.0M | -$13.7M | -$7.6M | -$15.2M | $2.4M | -$18.8M |
| Net margin | — | −181.7% | −88.5% | −1137.4% | −8175.9% | −4401.9% | −760.4% | −908.9% | 91.2% | −470.3% |
| Diluted EPS | $-2.26 | $-1.15 | $-0.83 | $-1.18 | $-0.87 | $-0.88 | $-2.06 | $-5.17 | $0.90 | $-10.10 |
| EBITDA | -$106.3M | -$41.1M | -$23.0M | -$29.2M | -$20.7M | -$13.5M | -$7.6M | -$15.2M | -$12.7M | -$16.9M |
| Operating cash flow | -$69.8M | -$40.0M | -$25.6M | $4.9M | -$16.8M | -$10.1M | -$6.9M | -$13.8M | -$14.2M | -$14.5M |
| Free cash flow | -$81.2M | -$41.2M | -$26.9M | $1.5M | -$18.0M | -$10.6M | -$6.9M | -$14.1M | -$14.2M | -$14.7M |
| Diluted shares | 46.5M | 35.2M | 26.8M | 24.6M | 23.1M | 15.6M | 3.7M | 2.9M | 2.7M | 1.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $287.8M | $11.3M | $14.7M | $9.6M | $34.9M | $32.7M |
| Short-term investments | $30.3M | $140.2M | $24.8M | $31.8M | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $3.4M | $3.4M | $3.7M |
| Total assets | $355.9M | $170.5M | $58.7M | $50.1M | $41.3M | $34.6M |
| Total liabilities | $50.2M | $25.0M | $36.1M | $38.3M | $10.0M | $6.4M |
| Shareholders' equity | $305.8M | $145.5M | $22.6M | $11.8M | $31.4M | $28.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology